UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000027938 |
|---|---|
| Receipt number | R000031805 |
| Scientific Title | A phase III clinical study to compare the combination therapy of eribulin mesylate + trastuzumab + pertuzumab with paclitaxel or Docetaxel + trastuzumab + pertuzumab |
| Date of disclosure of the study information | 2017/06/28 |
| Last modified on | 2023/01/05 09:42:15 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2017/06/26 15:01:59 | ||
| 2 | Update | 2017/08/02 19:16:08 | Recruitment status |
|
| 3 | Update | 2018/08/23 17:45:25 | Public title |
|
| 4 | Update | 2018/08/24 10:11:28 | UMIN ID1 |
|
| 5 | Update | 2019/01/10 17:19:06 | Key inclusion criteria Key inclusion criteria |
|
| 6 | Update | 2019/09/05 16:22:41 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Address Last name of contact person Last name of contact person Zip code Address Address Organization Organization Address Address Tel |
|
| 7 | Update | 2019/09/05 16:28:14 | Date of IRB Anticipated trial start date Last follow-up date |
|
| 8 | Update | 2020/06/29 21:21:10 | Last follow-up date |
|
| 9 | Update | 2021/07/02 20:13:17 | Last name of contact person Last name of contact person Division name Name of person sending information Name of person sending information Division name |
|
| 10 | Update | 2021/07/15 13:55:40 | Recruitment status |
|
| 11 | Update | 2021/07/15 15:41:55 | Homepage URL |
|
| 12 | Update | 2023/01/05 09:42:15 | Number of participants that the trial has enrolled |
